Bayer Stock Wavers Between Technical Hopes and Legal Fears as Promising Kidney Data Emerges

Bayer stock up 1.58% to €35.95, above 200-day MA; Kerendia trial success for non-diabetic CKD boosts pharma, but glyphosate legal overhang caps gains.

Bayer’s shares ended the trading week on a precarious footing, closing just above a key technical threshold even as the pharma division delivered the kind of clinical news that can open billion-dollar markets. The stock edged up 1.58% on Friday to finish at €35.95, barely clearing the 200-day simple moving average of €35.80 by a razor-thin 0.41%. That cushion is so small it offers little more than a technical lifeline rather than a genuine trend shift.

The mid-term picture remains strained. Over the past 30 days, the shares have lost 6.67%, and the year-to-date deficit stands at 5.46%. Two nearer-term resistance levels loom overhead: the 50-day moving average at €38.39 and the 100-day average at €40.50. A meaningful recovery would require piercing the first of those hurdles, which still sits roughly 6.4% above the current price. The 14-day relative strength index at 42.6 suggests there is technical room to the upside, but the annualized 30-day volatility of nearly 37% underscores how jumpy the market remains around this stock.

Adding to the mixed picture, Bayer’s pharma arm presented full Phase III results from the FIND-CKD trial at the ERA congress in Glasgow on Friday. The data showed that Kerendia significantly slowed disease progression in patients with non-diabetic chronic kidney disease and reduced the risk of combined cardiovascular events versus placebo. The company now plans to submit the results to the U.S. Food and Drug Administration to expand the drug’s label. Since non-diabetic kidney disease accounts for the majority of the estimated 850 million people affected globally, the potential market is substantial.

Yet all such fundamental progress is shadowed by the legal overhang that has dominated Bayer’s narrative. The source of the recent weakness was a procedural transfer in the glyphosate class-action complex in early June, which rekindled uncertainty. The market’s gaze is now fixed on Washington, where the U.S. Supreme Court is expected to rule on the “Durnell” case by the end of July 2026. That decision will determine the direction of the glyphosate liabilities and, by extension, the stock’s trajectory.

For the coming week, the €35.80 level acts as a critical support line. A sustained break below that would open the door to the next floor at €35.00, with the 52-week low of €25.09 – last visited in August 2025 – re-emerging as a distant reference point. Until the court delivers its verdict, every technical bounce will remain fragile, leaving investors balancing a promising pharma pipeline against a menacing legal calendar.